Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

522 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, Lacour JP, Ballotti R, Deckert M, Tartare-Deckert S. Fenouille N, et al. Among authors: lacour jp. PLoS One. 2012;7(7):e40378. doi: 10.1371/journal.pone.0040378. Epub 2012 Jul 20. PLoS One. 2012. PMID: 22911700 Free PMC article.
Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C. Bonet C, et al. Among authors: lacour jp. J Biol Chem. 2012 Aug 24;287(35):29887-98. doi: 10.1074/jbc.M112.371682. Epub 2012 Jul 5. J Biol Chem. 2012. PMID: 22767597 Free PMC article.
Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.
Tichet M, Prod'Homme V, Fenouille N, Ambrosetti D, Mallavialle A, Cerezo M, Ohanna M, Audebert S, Rocchi S, Giacchero D, Boukari F, Allegra M, Chambard JC, Lacour JP, Michiels JF, Borg JP, Deckert M, Tartare-Deckert S. Tichet M, et al. Among authors: lacour jp. Nat Commun. 2015 Apr 30;6:6993. doi: 10.1038/ncomms7993. Nat Commun. 2015. PMID: 25925867 Free article.
Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C, Luciani F, Ottavi JF, Leclerc J, Jouenne FM, Boncompagni M, Bille K, Hofman V, Bossis G, Marco de Donatis G, Strub T, Cheli Y, Ohanna M, Luciano F, Marchetti S, Rocchi S, Birling MC, Avril MF, Poulalhon N, Luc T, Hofman P, Lacour JP, Davidson I, Bressac-de Paillerets B, Ballotti R, Marine JC, Bertolotto C. Bonet C, et al. Among authors: lacour jp. J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw340. J Natl Cancer Inst. 2017. PMID: 28376192 Free article.
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS).
Ohanna M, Giuliano S, Bonet C, Imbert V, Hofman V, Zangari J, Bille K, Robert C, Bressac-de Paillerets B, Hofman P, Rocchi S, Peyron JF, Lacour JP, Ballotti R, Bertolotto C. Ohanna M, et al. Among authors: lacour jp. Genes Dev. 2011 Jun 15;25(12):1245-61. doi: 10.1101/gad.625811. Epub 2011 Jun 6. Genes Dev. 2011. PMID: 21646373 Free PMC article.
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype.
Ohanna M, Cheli Y, Bonet C, Bonazzi VF, Allegra M, Giuliano S, Bille K, Bahadoran P, Giacchero D, Lacour JP, Boyle GM, Hayward NF, Bertolotto C, Ballotti R. Ohanna M, et al. Among authors: lacour jp. Oncotarget. 2013 Dec;4(12):2212-24. doi: 10.18632/oncotarget.1143. Oncotarget. 2013. PMID: 24344100 Free PMC article.
Metformin monotherapy in melanoma: a pilot, open-label, prospective, and multicentric study indicates no benefit.
Montaudié H, Cerezo M, Bahadoran P, Roger C, Passeron T, Machet L, Arnault JP, Verneuil L, Maubec E, Aubin F, Granel F, Giacchero D, Hofman V, Lacour JP, Maryline A, Ballotti R, Rocchi S. Montaudié H, et al. Among authors: lacour jp. Pigment Cell Melanoma Res. 2017 May;30(3):378-380. doi: 10.1111/pcmr.12576. Epub 2017 Apr 22. Pigment Cell Melanoma Res. 2017. PMID: 28122176 Clinical Trial. No abstract available.
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
Allegra M, Giacchero D, Segalen C, Dumaz N, Butori C, Hofman V, Hofman P, Lacour JP, Bertolotto C, Bahadoran P, Ballotti R. Allegra M, et al. Among authors: lacour jp. J Invest Dermatol. 2014 May;134(5):1473-1476. doi: 10.1038/jid.2013.525. Epub 2013 Dec 6. J Invest Dermatol. 2014. PMID: 24317392 Free article. No abstract available.
522 results